Posts filed under ‘Medicina del viajero’

Editor’s Choice: Coinfection With Zika and Dengue-2 Viruses in a Traveler Returning From Haiti, 2016: Clinical Presentation and Genetic Analysis

Clinical Infectious Diseases January 1, 2017 V.64 N.1 P.72-75

BRIEF REPORTS

Nicole M. Iovine, John Lednicky, Kartikeya Cherabuddi, Hannah Crooke, Sarah K. White, Julia C. Loeb, Eleonora Cella, Massimo Ciccozzi, Marco Salemi, and J. Glenn Morris, Jr

1Division of Infectious Diseases, Department of Medicine, College of Medicine

2Emerging Pathogens Institute

3Department of Environmental and Global Health, College of Public Health and Health Professions

4Department of Epidemiology, College of Public Health and Health Professions

5Department of Pathology, Immunology and Laboratory Sciences, College of Medicine, University of Florida, Gainesville

6Department of Infectious Parasitic and Immunomediated Diseases, Reference Centre on Phylogeny, Molecular Epidemiology and Microbial Evolution/Epidemiology Unit, Istituto Superiore di Sanita, Rome, Italy

Zika virus and dengue virus serotype 2 were isolated from a patient with travel to Haiti who developed fever, rash, arthralgias, and conjunctivitis. The infecting Zika virus was related to Venezuelan and Brazilian strains but evolved along a lineage originating from strains isolated in 2014 in the same region of Haiti.

PDF

https://cid.oxfordjournals.org/content/64/1/72.full.pdf+html

August 19, 2017 at 10:26 am

EDITORIAL – Oropuche virus: A virus present but ignored

Rev.MVZ Córdoba 20(3):4675-4676, 2015

Virus de Oropuche: Un virus ignorado pero presente

El virus de Oropouche deriva su nombre de la localidad de Vegas de Oropuche, la cual se encuentra en la isla de Trinidad y Tobago, en donde fue detectado en 1955 en un paciente febril y en mosquitos Coquilletidia venezuelenzis.

El virus de Oropouche es prevalente en muchas regiones de América del Sur y del Caribe.

En el ciclo silvestre, el virus tiene varios mosquitos vectores: Culicoides paraensis, Coquilletidia venezuelenzis y Aedes serratus.

Los mamíferos silvestres son picados por estos mosquitos y aumentan las viremias, como en el oso perezoso (Bradypus tridactiyus), primates (Aloutta sanguinus) y roedores entre otros.

En el ciclo urbano los vectores son mosquitos Culicoides paraensis y Culex quinquefasciatus, ambos muy comunes en los ambientes tropicales de Colombia …

PDF

http://www.scielo.org.co/pdf/mvz/v20n3/v20n3a01.pdf

August 16, 2017 at 2:02 pm

Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure — United States (Including U.S. Territories), July 2017

MMWR July 28, 2017 V.66 N.29 P.781-793

Update

Titilope Oduyebo, MD1; Kara D. Polen, MPH1; Henry T. Walke, MD1; Sarah Reagan-Steiner, MD1; Eva Lathrop, MD1; Ingrid B. Rabe, MBChB1; Wendi L. Kuhnert-Tallman, PhD1; Stacey W. Martin, MSc1; Allison T. Walker, PhD1; Christopher J. Gregory, MD1; Edwin W. Ades, PhD1; Darin S. Carroll, PhD1; Maria Rivera, MPH1; Janice Perez-Padilla, MPH1; Carolyn Gould, MD1; Jeffrey B. Nemhauser, MD1; C. Ben Beard, PhD1; Jennifer L. Harcourt, PhD1; Laura Viens, MD1; Michael Johansson, PhD1; Sascha R. Ellington, MSPH1; Emily Petersen, MD1; Laura A. Smith, MA1; Jessica Reichard, MPA1; Jorge Munoz-Jordan, PhD1; Michael J. Beach, PhD1; Dale A. Rose, PhD1; Ezra Barzilay, MD1; Michelle Noonan-Smith1; Denise J. Jamieson, MD1; Sherif R. Zaki, MD1; Lyle R. Petersen, MD1; Margaret A. Honein, PhD1; Dana Meaney-Delman, MD1

CDC has updated the interim guidance for U.S. health care providers caring for pregnant women with possible Zika virus exposure in response to 1) declining prevalence of Zika virus disease in the World Health Organization’s Region of the Americas (Americas) and 2) emerging evidence indicating prolonged detection of Zika virus immunoglobulin M (IgM) antibodies.

Zika virus cases were first reported in the Americas during 2015–2016; however, the incidence of Zika virus disease has since declined.

As the prevalence of Zika virus disease declines, the likelihood of false-positive test results increases. In addition, emerging epidemiologic and laboratory data indicate that, as is the case with other flaviviruses, Zika virus IgM antibodies can persist beyond 12 weeks after infection.

Therefore, IgM test results cannot always reliably distinguish between an infection that occurred during the current pregnancy and one that occurred before the current pregnancy, particularly for women with possible Zika virus exposure before the current pregnancy.

These limitations should be considered when counseling pregnant women about the risks and benefits of testing for Zika virus infection during pregnancy.

This updated guidance emphasizes a shared decision-making model for testing and screening pregnant women, one in which patients and providers work together to make decisions about testing and care plans based on patient preferences and values, clinical judgment, and a balanced assessment of risks and expected outcomes…..

PDF

https://www.cdc.gov/mmwr/volumes/66/wr/pdfs/mm6629e1.pdf

July 28, 2017 at 5:17 pm

False-Positive Rapid Malaria Antigen Test Result in a Returned Traveler

Journal of Clinical Microbiology August 2017 V.55 N.8 P.2294-2297

The Brief Case

Kristle L. Haberichter, Paul C. Johnson, Paul J. Chittick, Peter Millward, Barbara Robinson-Dunn, and Bobby L. Boyanton Jr.

A previously healthy 43-year-old female presented to her primary care physician with a 13-day history of recurrent nightly fevers (100°F to 101°F), nonproductive cough, and respiratory congestion. She was prescribed azithromycin, albuterol, and benzonatate. She presented to the emergency center 2 days later without improvement and at that time reported night sweats. She had recently traveled to Thailand, Laos, Cambodia, and the United Arab Emirates. The nightly fevers began 11 days after returning home. She acknowledged being bitten by mosquitoes throughout her travels and did not take malaria prophylaxis.

A previously healthy 43-year-old female presented to her primary care physician with a 13-day history of recurrent nightly fevers (100°F to 101°F), nonproductive cough, and respiratory congestion. She was prescribed azithromycin, albuterol, and benzonatate. She presented to the emergency center 2 days later without improvement and at that time reported night sweats. She had recently traveled to Thailand, Laos, Cambodia, and the United Arab Emirates. The nightly fevers began 11 days after returning home. She acknowledged being bitten by mosquitoes throughout her travels and did not take malaria prophylaxis….

PDF

http://jcm.asm.org/content/55/8/2294.full.pdf+html

 

 

Journal of Clinical Microbiology August 2017 V.55 N.8 P.2560-2561

Closing the Brief Case: False-Positive Rapid Malaria Antigen Test Result in a Returned Traveler

Kristle L. Haberichter, Paul C. Johnson, Paul J. Chittick, Peter Millward, Barbara Robinson-Dunn, and Bobby L. Boyanton Jr.

aDepartment of Pathology and Laboratory Medicine, Beaumont Health, Royal Oak, Michigan, USA

bDepartment of Infectious Disease, Beaumont Health, Royal Oak, Michigan, USA

cOakland University William Beaumont School of Medicine, Rochester, Michigan, USA

ANSWERS TO SELF-ASSESSMENT QUESTIONS

PDF

http://jcm.asm.org/content/55/8/2560.full.pdf+html

July 26, 2017 at 9:23 am

LEPTOSPIROSIS – GUIA para el Equipo de Salud. Ministerio de Salud de la Nación Argentina – ABRIL 2014

INDICE

Pág 3. Información para el equipo de salud:

  1. Introducción
  2. Manifestaciones clínicas
  3. ¿Cuándo sospechar leptospirosis?
  4. ¿Cómo confirmar leptospirosis?
  5. ¿Cómo notificar el caso de leptospirosis?
  6. ¿Cómo se trata el paciente con leptospirosis?
  7. Flujograma de manejo de casos sospechosos de leptospirosis
  8. Diagnóstico diferencial
  9. ¿Qué hacer si se confirma?
  10. ¿Cómo se tratan los casos caninos de leptospirosis?
  11. Prevención de la leptospirosis en la familia y la comunidad

Pág 25. Recomendaciones para la organización de las actividades en el Equipo de Salud

  1. ¿Qué pueden Ud y su equipo de salud hacer para contribuir al control de la leptospirosis en su área?

Pág 29. Información para la población

  1. ¿Qué es la leptospirosis?
  2. ¿Cómo se transmite la leptospirosis?
  3. ¿Cómo ingresa la bacteria?
  4. ¿Cuáles son los síntomas de la leptospirosis?
  5. ¿Qué hacer en caso de padecer de algunos de los síntomas mencionados antes?
  6. ¿Cuál es el tratamiento?

7 ¿Cómo afecta la enfermedad a los animales domésticos?

  1. ¿Qué podemos hacer para prevenir la leptospirosis?

Pág 35. Anexos

  1. Muestras clínicas para examen
  2. Notificación a través del Módulo SIVILA del SNVS
  3. Bioseguridad
  4. Laboratorios de la Red de leptospirosis
  5. Algoritmo de diagnóstico y notificación por laboratorio
  6. Ficha de notificación de casos de síndrome febril
  7. Ficha de notificación de caso leptospirosis canina

PDF

http://www.msal.gob.ar/images/stories/bes/graficos/0000000489cnt-guia-medica-leptospirosis.pdf

July 17, 2017 at 8:32 am

Surveillance and outbreak report LEGIONNAIRES’ DISEASE IN EUROPE, 2011 TO 2015

Eurosurveillance July 06, 2017 V.22 N.27

J Beauté 1 2 , on behalf of the European Legionnaires’ Disease Surveillance Network 3

  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
  3. The members of the network are listed at the end of the article

Under the coordination of the European Centre for Disease Prevention and Control (ECDC), the European Legionnaires’ disease Surveillance Network (ELDSNet) conducts surveillance of Legionnaires’ disease (LD) in Europe. Between 2011 and 2015, 29 countries reported 30,532 LD cases to ECDC (28,188 (92.3%) confirmed and 2,344 (7.7%) probable). Four countries (France, Germany, Italy and Spain) accounted for 70.3% of all reported cases, although their combined populations represented only 49.9% of the study population. The age-standardised rate of all cases increased from 0.97 cases/100,000 population in 2011 to 1.30 cases/100,000 population in 2015, corresponding to an annual average increase of 0.09 cases/100,000 population (95%CI 0.02–0.14; p = 0.02). Demographics and infection setting remained unchanged with ca 70% of cases being community-acquired and 80% occurring in people aged 50 years and older. Clinical outcome was known for 23,164 cases, of whom 2,161 (9.3%) died. The overall case fatality ratio decreased steadily from 10.5% in 2011 to 8.1% in 2015, probably reflecting improved reporting completeness. Five countries (Austria, Czech Republic, Germany, Italy, and Norway) had increasing age-standardised LD notification rates over the 2011−15 period, but there was no increase in notification rates in countries where the 2011 rate was below 0.5/100,000 population….

FULL TEXT

http://eurosurveillance.org/ViewArticle.aspx?ArticleId=22829

PDF

http://eurosurveillance.org/images/dynamic/EE/V22N27/art22829.pdf

July 12, 2017 at 8:20 am

Epidemiology of human plague in the United States, 1900-2012.

Emerg Infect Dis. 2015 Jan;21(1):16-22.

Kugeler KJ, Staples JE, Hinckley AF, Gage KL, Mead PS.

Abstract

We summarize the characteristics of 1,006 cases of human plague occurring in the United States over 113 years, beginning with the first documented case in 1900.

Three distinct eras can be identified on the basis of the frequency, nature, and geographic distribution of cases. During 1900-1925, outbreaks were common but were restricted to populous port cities.

During 1926-1964, the geographic range of disease expanded rapidly, while the total number of reported cases fell. During 1965-2012, sporadic cases occurred annually, primarily in the rural Southwest.

Clinical and demographic features of human illness have shifted over time as the disease has moved from crowded cities to the rural West.

These shifts reflect changes in the populations at risk, the advent of antibiotics, and improved detection of more clinically indistinct forms of infection.

Overall, the emergence of human plague in the United States parallels observed patterns of introduction of exotic plants and animals.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285253/pdf/14-0564.pdf

June 29, 2017 at 8:17 am

Older Posts


Calendar

August 2017
M T W T F S S
« Jul    
 123456
78910111213
14151617181920
21222324252627
28293031  

Posts by Month

Posts by Category